SYDNEY–(BUSINESS WIRE)–AdvanCell, a clinical-stage radiopharmaceutical company developing innovative cancer therapeutics, today announced $18M in Australian Federal Government Funding from the Medical Research Future Fund (MRFF) Frontiers Initiative for ‘Defeating Prostate Cancer with Targeted Alpha Therapy’. One out of eight men develops prostate cancer. With the support from the Medical Research Future Fund (MRFF) Frontiers Initiative, the goal of the multidisciplinary multi-institutional i
http://www.businesswire.com/images/Powered-by-Business-Wire.gifGo to Source
https://feed.businesswire.com/rss/home/?rss=G1QFDERJXkJeEVlZWA==&_gl=1*1m4yt6c*_gcl_au*ODY2ODgwODguMTczNjM1MjA5OA..*_ga*MTQ4NTQ4MjYyMi4xNzM2MzUyMDk4*_ga_ZQWF70T3FK*MTczNjM1MjA5OC4xLjEuMTczNjM1MjIwOS42MC4wLjA.